Johnson & Johnson
2016 sales: $843 million
With pulmonary arterial hypertension blockbuster Tracleer aging, Actelion in 2013 won FDA approval for Opsumit, a new-and-improved product competing in the same space. And since then, the newcomer and fellow PAH product Uptravi—which won its FDA green light in December 2015—have been able to make up for the hole Tracleer’s decline has left.
Between 2015 and 2016, Opsumit’s sales grew to CHF 831 million from CHF 516 million, marking an increase of 57% at constant exchange rates. In addition to the U.S., sales came from Germany, Japan and more than 40 other countries.
And the way new owner Johnson & Johnson—which this year closed a $30 billion deal for Actelion’s marketed meds—sees it, it’ll be able to bump those numbers up thanks to its marketing reach. “We expect to leverage our established global presence and commercial strength to accelerate growth and patient access to these important therapies,” J&J CEO Alex Gorsky said in a statement when the deal was announced in January.
Meanwhile, though, the Opsumit expansion effort recently hit a snag when the med flunked a phase 3 trial in patients whose PAH is caused by heart disorder Eisenmenger Syndrome. A six-minute walk test caused the problems; Opsumit, though it did spur improvements in cardiac stress and heart pumping function, did not significantly improve patients’ ability to perform the test. But Evaluate Pharma analysts still predict that the med's sales will grow from $843 million in 2016 to $1.75 billion in 2022.